喉癌放射抵抗的确切机制尚未阐明，近年来发现肿瘤干细胞在肿瘤放射抵抗中起重要作用，已证实喉癌CDl33+细胞具有肿瘤干细胞特性。本课题组首次发现喉癌细胞放射抵抗与Glut-1表达有关。而CD133+细胞Glut-1表达与喉癌放射抵抗的关系，迄今国内外尚无报道。前期研究我们发现反义Glut-1能降低喉癌细胞Glut-1表达继而提高喉癌放射敏感性，预实验发现CD133+喉癌细胞Glut-1高表达。因此，我们提出抑制CD133+喉癌细胞Glut-1表达可提高喉癌放射敏感性的假说。为证实这一假说，我们将通过检测喉癌细胞放射前后CD133+ 喉癌细胞及Glut-1表达变化，验证CD133+喉癌细胞与放射抵抗有关，明确这种放射抵抗与CD133+喉癌细胞Glut-1表达密切相关；从体内外实验研究靶向抑制CD133+ 喉癌细胞Glut-1表达而提高喉癌放射敏感性的机制，为喉癌患者保留喉功能治疗提供新理论。

The exact mechanism of the radioresistance of laryngeal carcinoma remains unclear. Recently, cancer stem cells (CSC) were found to play an important role in radioresistance. CD133+ cells are a useful marker for CSCs in human laryngeal carcinoma. We found that increased Glut-1 expression was associated with the radioresistance of laryngeal carcinoma. To our knowledge, no study has examined the relationship between Glut-1 expression in laryngeal CSCs and radioresistance. Previously, we found that antisense Glut-1 decreases the expression of Glut-1 in laryngeal carcinoma, which improves the radiosensitivity of laryngeal carcinoma. In a preliminary study, we also found that CD133+ cells proliferated more. Glut-1 mRNA and protein levels were higher in CD133+ cells than in CD133- cells. Therefore, we speculated that the inhibition of Glut-1 expression in laryngeal CD133+Hep-2 cells might improve the radiosensitivity of laryngeal carcinoma. To test this hypothesis, we assessed the change in CD133+ Hep-2 cells and Glut-1 expression in laryngeal carcinoma cells before and after radiotherapy to determine whether CD133+Hep-2 cells are associated with the radioresistance of laryngeal carcinoma. We found that the radioresistance of laryngeal carcinoma was associated with increased Glut-1 expression in CD133+ Hep-2 cells. Based on these results, we developed a new hypothesis regarding the preservation of laryngeal function in patients with laryngeal carcinoma via targeted inhibition of Glut-1 expression in CD133+ Hep-2 cells to improve the radiosensitivity of laryngeal carcinoma.